Pulmonary Hypertension in Portugal: First Data from a Nationwide Registry

Table 5

Pulmonary vasodilator therapies at follow-up of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients.

	PAH	CTEPH
No advanced therapies	2%	33%
Single therapy	50%	36%
Double combination therapy	28%	15%
Triple combination therapy	9%	7%
Calcium channel blockers	7%	0%
Randomized controlled trial drug	4%	3%